Novo Nordisk said on Thursday it would offer temporary discounts to cash-paying customers for its weight-loss drug Wegovy, in a move that coincides with a deadline for halting sales of cheaper compounded versions.

Novo Nordisk (NVO) stock in focus as the company promotes FDA-approved Wegovy as a ban for makers of compounding versions take effect. Read more here.

Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the company’s board of directors, citing “recent market challenges” and a steep decline in the company’s share price.